Table 1 Novel ADCs in early clinical research in ALL
From: Recent updates for antibody therapy for acute lymphoblastic leukemia
Antibody | Target | Payload | Phase of trial | Setting | Identifier |
|---|---|---|---|---|---|
ADCT-602 | CD22 | PBD-dimer toxin | I/II | R/R CD22+ | NCT03698552 |
ADCT-402 (loncastuximab tesirine) | CD19 | PBD-dimer toxin | I | R/R | NCT02669264 |
SGN-CD19A (denintuzumab mafodotin) | CD19 | monomethyl auristatin F (MMAF) | I | R/R Ph− | NCT01786096 |
ADCT-301 (camidanlumab tesirine) | CD25 | PBD-dimer toxin | I | R/R CD25+ AML/ALL | NCT02588092 |
IMGN632 | CD123 | IGN | I | R/R CD123+ | NCT03386513 |